Clinical Proteomics in Diabetes and its Complications, July 20, 2007, Lister Hill Auditorium, Building 38A, NIH, Bethesda, MD
Clinical Proteomics in Diabetes and its Complications, July 20, 2007, Lister Hill Auditorium, Building 38A, NIH, Bethesda, MD
Home registration agenda Logistics Contact
Clinical Proteomics in Diabetes and its Complications, July 20, 2007, Lister Hill Auditorium, Building 38A, NIH, Bethesda, MD
Discussion Questions
  • What are the sample requirements for proteomic studies?
  • Are the samples collected from the above studies suitable for molecular marker discovery and mechanistic studies using proteomic technologies?
  • Are there other clinical investigations that could be seen as more appropriate for proteomic analysis intended to identify/characterize markers of diabetes and its complications?
  • Do you envision that some of the technologies presented here could be successfully used to analyze samples collected within the clinical studies presented?
  • Can any particular technologies presented here be especially well matched with any of the clinical investigations presented here?
  • For example, do you think that these technologies are sufficiently mature to address issues such as population stratification in response to treatment in pilot studies?
  • If yes, how many samples should be tested in a population stratification pilot study?
 
Clinical Proteomics in Diabetes and its Complications, July 20, 2007, Lister Hill Auditorium, Building 38A, NIH, Bethesda, MD
Department of Health and Human Services National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases